Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Generate Biomedicines, Inc.NASDAQ: GENB
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin at -887.5%
Operating margin was -887.5% in Q1 FY2026.
What to watch
Whether operating margin reaches the consensus estimate from 4 analysts of -539.8% for the fiscal year ending Dec 2026, up from -737.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -887.5%— QoQ
- Last fiscal yearDec 2025
- -737.0%+225.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +225.6 pp | +197.2 pp | -28.3 pp |
| 3 years | — | +619.9 pp | — |
| 5 years | +658.9 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -737.0%
- Year-over-year change
- +225.6pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -737.0% | +225.6pp |
| FY2024 | 2024-12-31 | -962.6% | — |
Operating Margin vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 operating margin of -737.0% is the 3rd highest of the 5 companies compared; the peer median is -3649.4%.
- Its year-over-year change of +225.6 pp is the 4th highest of 5, against a peer median of +351.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -115.5% | +261.4 pp | +87.9 pp | |
| LTM Sep 2026 | -298.0% | +441.7 pp | -333.6 pp | |
GENBGenerate Biomedicines, Inc. | FY2025 | -737.0% | +225.6 pp | — |
| LTM Mar 2026 | -7000.8% | -4651.5 pp | -2596.7 pp | |
| LTM Mar 2026 | -9465.5% | +140796.5 pp | -4496.2 pp | |
| Peer median (excluding GENB) | -3649.4% | +351.5 pp | -1465.2 pp | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 20.46M | 31.89M |
| Gross Margin | 100.0% | 100.0% |
| Research & Development | 175.31M | 224.7M |
| Selling, General & Admin | 42.09M | 42.26M |
| Operating Expenses | 217.4M | 266.96M |
| Depreciation & Amortization | 15.35M | 13.18M |
| EBITDA | (163.71M) | (208.49M) |
| EBITDA Margin | -800.2% | -653.7% |
| Operating Income | (196.94M) | (235.07M) |
| Operating Margin | -962.6% | -737.0% |
| Interest Income | 18.12M | 13.66M |
| Interest Expense | 2.12M | 1.14M |
| Other Income / Expenses | 15.77M | 12.26M |
| Income Before Tax | (181.17M) | (222.8M) |
| Pre-Tax Margin | -885.5% | -698.6% |
| Income Tax Expense | 212K | 163K |
| Net Income | (173.77M) | (203.15M) |
| Net Margin | -849.4% | -637.0% |
| EPS (Basic) | (1.68) | (4.98) |
| EPS (Diluted) | (1.68) | (4.98) |
| Weighted Avg Shares | 127.45M | 50.09M |
| Weighted Avg Shares (Diluted) | 127.45M | 50.09M |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.